412 related articles for article (PubMed ID: 34153117)
1. Erenumab treatment for migraine prevention in Japanese patients: Efficacy and safety results from a Phase 3, randomized, double-blind, placebo-controlled study.
Takeshima T; Sakai F; Hirata K; Imai N; Matsumori Y; Yoshida R; Peng C; Cheng S; Mikol DD
Headache; 2021 Jun; 61(6):927-935. PubMed ID: 34153117
[TBL] [Abstract][Full Text] [Related]
2. Long-term efficacy and safety during open-label erenumab treatment in Japanese patients with episodic migraine.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Cheng S; Numachi Y; Peng C; Xue F; Mikol DD
Headache; 2021 Apr; 61(4):653-661. PubMed ID: 33764538
[TBL] [Abstract][Full Text] [Related]
3. A Randomized Phase 2 Study of Erenumab for the Prevention of Episodic Migraine in Japanese Adults.
Sakai F; Takeshima T; Tatsuoka Y; Hirata K; Lenz R; Wang Y; Cheng S; Hirama T; Mikol DD
Headache; 2019 Nov; 59(10):1731-1742. PubMed ID: 31612482
[TBL] [Abstract][Full Text] [Related]
4. One-year sustained efficacy of erenumab in episodic migraine: Results of the STRIVE study.
Goadsby PJ; Reuter U; Hallström Y; Broessner G; Bonner JH; Zhang F; Wright IK; Chou DE; Klatt J; Picard H; Lenz RA; Mikol DD
Neurology; 2020 Aug; 95(5):e469-e479. PubMed ID: 32636324
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of erenumab in women with a history of menstrual migraine.
Pavlovic JM; Paemeleire K; Göbel H; Bonner J; Rapoport A; Kagan R; Zhang F; Picard H; Mikol DD
J Headache Pain; 2020 Aug; 21(1):95. PubMed ID: 32746775
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study.
Reuter U; Goadsby PJ; Ferrari MD; Da Silva Lima GP; Mondal S; Kalim J; Hasan F; Wen S; Arkuszewski M; Pandhi S; Stites T; Lanteri-Minet M
Neurology; 2024 May; 102(10):e209349. PubMed ID: 38669638
[TBL] [Abstract][Full Text] [Related]
7. A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study.
Yu S; Kim BK; Wang H; Zhou J; Wan Q; Yu T; Lian Y; Arkuszewski M; Ecochard L; Wen S; Yin F; Li Z; Su W; Wang SJ
J Headache Pain; 2022 Nov; 23(1):146. PubMed ID: 36404301
[TBL] [Abstract][Full Text] [Related]
8. Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study.
Ferrari MD; Reuter U; Goadsby PJ; Paiva da Silva Lima G; Mondal S; Wen S; Tenenbaum N; Pandhi S; Lanteri-Minet M; Stites T
J Neurol Neurosurg Psychiatry; 2022 Mar; 93(3):254-262. PubMed ID: 34845002
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study.
Reuter U; Goadsby PJ; Lanteri-Minet M; Wen S; Hours-Zesiger P; Ferrari MD; Klatt J
Lancet; 2018 Nov; 392(10161):2280-2287. PubMed ID: 30360965
[TBL] [Abstract][Full Text] [Related]
10. Long-term efficacy and safety of erenumab in Japanese patients with episodic and chronic migraine: results from a 28-week open-label treatment period of a randomised trial.
Hirata K; Takeshima T; Sakai F; Numachi Y; Yoshida R; Koukakis R; Hasebe M; Yui D; da Silva Lima GP; Cheng S
BMJ Open; 2023 Aug; 13(8):e068616. PubMed ID: 37597868
[TBL] [Abstract][Full Text] [Related]
11. Long-term (48 weeks) effectiveness, safety, and tolerability of erenumab in the prevention of high-frequency episodic and chronic migraine in a real world: Results of the EARLY 2 study.
Barbanti P; Aurilia C; Cevoli S; Egeo G; Fofi L; Messina R; Salerno A; Torelli P; Albanese M; Carnevale A; Bono F; D'Amico D; Filippi M; Altamura C; Vernieri F;
Headache; 2021 Oct; 61(9):1351-1363. PubMed ID: 34309862
[TBL] [Abstract][Full Text] [Related]
12. Reduction in acute migraine-specific and non-specific medication use in patients treated with erenumab: post-hoc analyses of episodic and chronic migraine clinical trials.
Tepper SJ; Ashina M; Reuter U; Hallström Y; Broessner G; Bonner JH; Picard H; Cheng S; Chou DE; Zhang F; Klatt J; Mikol DD
J Headache Pain; 2021 Jul; 22(1):81. PubMed ID: 34301173
[TBL] [Abstract][Full Text] [Related]
13. Early onset of efficacy with erenumab for migraine prevention in Japanese patients: Analysis of two randomized, double-blind, placebo-controlled studies.
Hirata K; Takeshima T; Sakai F; Imai N; Matsumori Y; Tatsuoka Y; Numachi Y; Yoshida R; Peng C; Mikol DD; Lima GPDS; Cheng S
Brain Behav; 2022 Mar; 12(3):e2526. PubMed ID: 35201674
[TBL] [Abstract][Full Text] [Related]
14. ARISE: A Phase 3 randomized trial of erenumab for episodic migraine.
Dodick DW; Ashina M; Brandes JL; Kudrow D; Lanteri-Minet M; Osipova V; Palmer K; Picard H; Mikol DD; Lenz RA
Cephalalgia; 2018 May; 38(6):1026-1037. PubMed ID: 29471679
[TBL] [Abstract][Full Text] [Related]
15. The Spectrum of Response to Erenumab in Patients With Episodic Migraine and Subgroup Analysis of Patients Achieving ≥50%, ≥75%, and 100% Response.
Broessner G; Reuter U; Bonner JH; Dodick DW; Hallström Y; Picard H; Zhang F; Lenz RA; Klatt J; Mikol DD
Headache; 2020 Oct; 60(9):2026-2040. PubMed ID: 32851644
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: A subgroup analysis of a randomized, double-blind, placebo-controlled study.
Goadsby PJ; Paemeleire K; Broessner G; Brandes J; Klatt J; Zhang F; Picard H; Lenz R; Mikol DD
Cephalalgia; 2019 Jun; 39(7):817-826. PubMed ID: 30982348
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial.
Hirata K; Sakai F; Takeshima T; Imai N; Matsumori Y; Yoshida R; Numachi Y; Peng C; Mikol DD; Cheng S
J Headache Pain; 2021 Sep; 22(1):110. PubMed ID: 34537006
[TBL] [Abstract][Full Text] [Related]
18. Safety and tolerability of erenumab in individuals with episodic or chronic migraine across age groups: a pooled analysis of placebo-controlled trials.
Lampl C; Kraus V; Lehner K; Loop B; Chehrenama M; Maczynska Z; Ritter S; Klatt J; Snellman J
J Headache Pain; 2022 Aug; 23(1):104. PubMed ID: 35978286
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of erenumab in patients with chronic migraine in whom prior preventive treatments had failed: A subgroup analysis.
Ashina M; Tepper SJ; Brandes JL; Reuter U; Boudreau GP; Weatherall M; Gantenbein AR; Doležil D; Klatt J; Wang A; Karanam AK; Cheng S; Mikol DD
Headache; 2022 May; 62(5):624-633. PubMed ID: 35593783
[TBL] [Abstract][Full Text] [Related]
20. Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study.
Tepper SJ; Ashina M; Reuter U; Brandes JL; Doležil D; Silberstein SD; Winner P; Zhang F; Cheng S; Mikol DD
Cephalalgia; 2020 May; 40(6):543-553. PubMed ID: 32216456
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
